Health Care Costs, Utilization and Patterns of Care following Lyme Disease

被引:154
|
作者
Adrion, Emily R. [1 ,3 ]
Aucott, John [2 ]
Lemke, Klaus W.
Weiner, Jonathan P. [4 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MA USA
[2] Johns Hopkins Univ, Div Rheumatol, Johns Hopkins Greenspring Stn, Sch Med, Baltimore, MD 21218 USA
[3] Johns Hopkins Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
来源
PLOS ONE | 2015年 / 10卷 / 02期
关键词
BORRELIA-BURGDORFERI; UNITED-STATES; PREVENTION; IMPACT;
D O I
10.1371/journal.pone.0116767
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Lyme disease is the most frequently reported vector borne infection in the United States. The Centers for Disease Control have estimated that approximately 10% to 20% of individuals may experience Post-Treatment Lyme Disease Syndrome - a set of symptoms including fatigue, musculoskeletal pain, and neurocognitive complaints that persist after initial antibiotic treatment of Lyme disease. Little is known about the impact of Lyme disease or post-treatment Lyme disease symptoms (PTLDS) on health care costs and utilization in the United States. Objectives 1) to examine the impact of Lyme disease on health care costs and utilization, 2) to understand the relationship between Lyme disease and the probability of developing PTLDS, 3) to understand how PTLDS may impact health care costs and utilization. Methods This study utilizes retrospective data on medical claims and member enrollment for persons aged 0-64 years who were enrolled in commercial health insurance plans in the United States between 2006-2010. 52,795 individuals treated for Lyme disease were compared to 263,975 matched controls with no evidence of Lyme disease exposure. Results Lyme disease is associated with $2,968 higher total health care costs (95% CI: 2,8073,128, p<.001) and 87% more outpatient visits (95% CI: 86%-89%, p<.001) over a 12-month period, and is associated with 4.77 times greater odds of having any PTLDS-related diagnosis, as compared to controls (95% CI: 4.67-4.87, p<.001). Among those with Lyme disease, having one or more PTLDS-related diagnosis is associated with $3,798 higher total health care costs (95% CI: 3,542-4,055, p<.001) and 66% more outpatient visits ( 95% CI: 64%-69%, p<.001) over a 12-month period, relative to those with no PTLDS-related diagnoses. Conclusions Lyme disease is associated with increased costs above what would be expected for an easy to treat infection. The presence of PTLDS-related diagnoses after treatment is associated with significant health care costs and utilization.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Health care utilization and costs following Kawasaki disease
    Robinson, Cal
    Chanchlani, Rahul
    Gayowsky, Anastasia
    Darling, Elizabeth
    Seow, Hsien
    Batthish, Michelle
    PAEDIATRICS & CHILD HEALTH, 2022, 27 (03) : 160 - 168
  • [2] Evaluation of Health Care Costs and Utilization Patterns for Patients With Gout
    Park, Haesuk
    Rascati, Karen L.
    Prasla, Karim
    McBayne, Tyrone
    CLINICAL THERAPEUTICS, 2012, 34 (03) : 640 - 652
  • [3] Health Care Utilization Patterns and Costs for Patients With Hidradenitis Suppurativa
    Kirby, Joslyn S.
    Miller, Jeffery J.
    Adams, David R.
    Leslie, Douglas
    JAMA DERMATOLOGY, 2014, 150 (09) : 937 - 944
  • [4] Drinking patterns, health care utilization, and costs among HMO primary care patients
    Polen, MR
    Green, CA
    Freeborn, DK
    Mullooly, JP
    Lynch, F
    JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH, 2001, 28 (04): : 378 - 399
  • [5] Drinking patterns, health care utilization, and costs among HMO primary care patients
    Michael R. Polen
    Carla A. Green
    Donald K. Freeborn
    John P. Mullooly
    Frances Lynch
    The Journal of Behavioral Health Services & Research, 2001, 28 : 378 - 399
  • [6] Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease
    Mucha, Lisa
    Wang, Sara Shaohung
    Cuffel, Brian
    McRae, Thomas
    Mark, Tami L.
    del Valle, Megan
    JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (05): : 451 - 461
  • [7] Evaluation of health care costs and utilization patterns for patients with gout in Taiwan
    Lee, Yi-yun
    Ko, Yu
    PHARMACOTHERAPY, 2016, 36 (12): : E262 - E263
  • [8] Health care costs and utilization for Alzheimer's disease patients
    Zhao, Y.
    Kuo, T. C.
    Weir, S.
    Kramer, M. S.
    Ash, A. S.
    VALUE IN HEALTH, 2007, 10 (03) : A90 - A90
  • [9] EVALUATION OF HEALTH CARE COSTS AND UTILIZATION PATTERNS FOR PATIENTS WITH GOUT IN TAIWAN
    Lee, Y.
    Ko, Y.
    Wu, C.
    Tang, C.
    Kuo, L.
    VALUE IN HEALTH, 2016, 19 (07) : A916 - A916
  • [10] Availability, Health-Care Costs, and Utilization Patterns of Biologics in Taiwan
    Hsieh, Chee-Ruey
    Liu, Ya-Ming
    VALUE IN HEALTH, 2012, 15 (01) : S35 - S42